Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | S100A9 | P06702 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498458 | 1.00 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL31340962 | 0.83 | KMT2A (0.47) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1934159 | 0.83 | KMT2A (0.69) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1937546 | 0.81 | KMT2A (0.71) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1976634 | 0.80 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL22866360 | 0.80 | KMT2A (0.97) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL29860203 | 0.80 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1783010 | 0.80 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL13812811 | 0.80 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL13812813 | 0.80 | KMT2A (0.65) | KMT2AAXLADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024193393-A1 | CRYSTAL FORM OF HETEROPYRIDOPYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR | 成都金瑞基业生物科技有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-116529251-A | Substituted fused bicyclic compounds as kinase inhibitors and their use | 上海瑛派药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116284044-A | Crystal form and preparation method of hybrid pyridopyrimidinone derivative | 上海勋和医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | NUAK1, NUAK2, NEK11 | KMT2A 897/4885AXL 3338/4885ADORA3 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.